Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis

Ruzicka, Thomas; Hanifin, Jon M.; Furue, Masutaka; Pulka, Grażyna; Mlynarczyk, Izabela; Wollenberg, Andreas; Galus, Ryszard; Etoh, Takafumi; Mihara, Ryosuke; Yoshida, Hiroki; Stewart, Jerry E.; Kabashima, Kenji

doi:10.1056/nejmoa1606490

Cited by 496 publications

(423 citation statements)

References 39 publications

Supporting

Mentioning

388

Contrasting

Unclassified

Order By: Relevance

“…Side effects were nearly negligible encompassing increased creatine phosphokinase levels in the treatment group compared to placebo. A phase II study of nemolizumab in 264 AD patients (moderate to severe) unable to adequately control disease activity by topical therapy shows significantly decreased pruritus [58]. However, despite marked reductions of both the EASI and SCORAD severity scores, these changes did not reach levels of statistical significance possibly due to sample size.…”

Section: Nemolizumabmentioning

confidence: 99%

Emerging Treatment Options in Atopic Dermatitis: Systemic Therapies

Nygaard

Vestergaard

Deleuran³

2017

Dermatology

View full text Add to dashboard Cite

The pathogenesis of atopic dermatitis (AD) is multifactorial and intricate, and the clinical presentation of the condition varies greatly. Symptoms and severity depend on individual trigger factors and stage of the disease. The majority of AD patients are sufficiently treated with emollients in combination with existing topical or systemic therapies. Yet treatment failure with existing drugs and treatment options can be a significant clinical problem. New treatments are under development, and the majority of these new drugs focus on targeting a skewed immune response in AD. Novel therapeutic approaches, which target the pathways involved in the pathogenesis of AD, may provide a potentially more effective and less harmful approach to systemic therapy. These pharmaceutical agents are designed to narrowly modify or directly block a specific cellular signal or pro-inflammatory pathway. We review systemic drugs in the pipeline for AD. To make the review as current and pertinent as possible, we selected to focus on AD-related therapies available in the clinicaltrials.gov database with a first received date after January 1, 2014, up until May 31, 2017. We excluded therapies that could be categorized as either traditional Chinese medicine, herbal medicine, probiotics, histamine/leukotriene blockers, immuno-adsorption, or immunostimulants.

show abstract

Section: Nemolizumabmentioning

confidence: 99%

Emerging Treatment Options in Atopic Dermatitis: Systemic Therapies

Nygaard

Vestergaard

Deleuran³

2017

Dermatology

View full text Add to dashboard Cite

show abstract

“…Notably, therapy with ustekinumab that inhibits the common p40 subunit of IL-12/IL-23 and thus the production of IL-17, IL-21, and IL-22, was not effective in patients with moderate to very severe AD [153, 154]. A 12-week therapy with nemolizumab, the anti-IL-31 receptor antibody, was shown to dramatically reduce pruritus and in parallel improve clinical signs of AD in a phase 2 study underlining the role of the itch-scratch cycle [155]. …”

Section: Therapeutic Management Of Admentioning

confidence: 99%

Atopic Dermatitis: Collegium Internationale Allergologicum (CIA) Update 2019

Simon

Wollenberg

Renz

et al. 2019

Int Arch Allergy Immunol

Self Cite

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a chronic inflammatory skin disease presenting with recurrent eczematous lesions and intense pruritus. It is common and affects both children and adults, often beginning in infancy. Due to the unpredictable disease course, its visible skin lesions, itching and scratching followed by sleeplessness, other associated atopic diseases, and behavioral and psychiatric disorders, AD is an immense burden for patients and caregivers. AD is determined by a genetic predisposition characterized by an impaired skin barrier and a T-helper-2-predominant inflammation. Restoration of the skin barrier is the main approach for treating and preventing AD. In order to cope with acute flares, usually topical corticosteroids (TCS) are applied, while topical calcineurin inhibitors (TCI) are used mainly for maintenance therapy. There is a small group of patients who are refractory to TCS and TCI and require systemic immunosuppressive drugs such as ciclosporin. Novel, targeted therapies are under clinical investigation, among which an anti-IL-4/IL-13 receptor antibody has recently been approved in several countries. As we learn to understand the pathomechanisms of AD, the characteristics of the different patient subgroups, and the effectiveness of various targeted therapies, a personalized treatment ensuring the best efficacy and safety and, probably, a disease-modifying effect will result.

show abstract

“…In a recently published phase II trial, an anti-IL-31 receptor A antibody, nemolizumab, resulted in significantly improved pruritus in patients with moderate-to-severe atopic dermatitis. 10 In a companion article in this issue, Gangemi et al 11 reported on their systematic review, which provided a timely in-depth overview regarding the role of IL-31 in skin diseases.…”

mentioning

confidence: 99%